| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Our next-generation sequencing assay for noncolorectal GI cancer assists in diagnosis, including variations in the most commonly mutated PDGFRA and KIT genes, along with NF1, BRAF, and other RAS genes. The test also includes detection of SETD2 and TP53 mutations, which have been shown to take on an aggressive clinical course.
85%-90%
85%–90% of gastrointestinal stromal tumors are associated with mutations in the PDGRFA and KIT genes
Non-colorectal GI tumors Test menu
Key testing
Advantages
Highlights
Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.